Ophthalmology Times: Insights from the FARETINA and FARWIDE Studies
Overview of the FARETINA and FARWIDE Studies
The FARETINA and FARWIDE studies provide crucial insights into the real-world efficacy, durability, and safety of faricimab in treating diabetic macular edema. Dr. Durga Borkar discusses the findings and how they can revolutionize treatment strategies.
Real-World Data Collection
Data were gathered from the world's largest ophthalmology electronic health record registry, the IRIS registry, for the FARETINA study, conducted in the US. Meanwhile, the FARWIDE study collected data from NHS sites in the UK using the metasoft EHR.
Key Outcomes of the Studies
- Patients in the FARETINA study gained about 3 letters of vision after 6 injections.
- The FARWIDE study showed an improvement of 8 letters of visual acuity.
- Safety profiles were comparable to those in phase 3 clinical trials.
Implications for Retina Specialists
With impressive results in treatment-naive patients, retina specialists are encouraged to consider faricimab earlier in the treatment of diabetic macular edema. This could lead to decreased treatment burden and improved patient outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.